Prime to test FDA flexibility with 2-patient gene editing submission

The planned filing comes amid heightened scrutiny of the FDA’s rare disease stance and a year after Prime deprioritized the program for economic reasons. This submission marks a pivotal moment as it seeks to leverage the FDA’s evolving approach towards gene therapies, particularly in the context of rare diseases where traditional clinical trial frameworks may not be feasible.

As the FDA continues to navigate the complexities of approving innovative treatments, Prime’s decision to advance with a two-patient submission could set a precedent for future gene editing applications. The implications of this move extend beyond Prime, potentially influencing regulatory pathways for other companies in the gene therapy space. If successful, it may encourage a broader acceptance of smaller-scale studies, thereby accelerating the development of therapies for patients with unmet medical needs.